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Purpose: Argentina-Alzheimer’s Disease Neuroimaging Initiative (Arg-ADNI) is the first 
ADNI study to be performed in Latin America at a medical center with the appropriate 
infrastructure. Our objective was to describe baseline characteristics and to examine whether 
biomarkers related to Alzheimer’s disease (AD) physiopathology were associated with worse 
memory performance.
Patients and methods: Fifteen controls and 28 mild cognitive impairment and 13 AD dementia 
subjects were included. For Arg-ADNI, all biomarker parameters and neuropsychological tests of 
ADNI-II were adopted. Results of positron emission tomography (PET) with fluorodeoxyglucose 
and 11C-Pittsburgh compound-B (PIB-PET) were available from all participants. Cerebrospinal 
fluid biomarker results were available from 39 subjects.
Results: A total of 56 participants were included and underwent baseline evaluation. The three 
groups were similar with respect to years of education and sex, and they differed in age (F=5.10, 
P=0.01). Mean scores for the baseline measurements of the neuropsychological evaluation differed 
significantly among the three groups at P,0.001, showing a continuum in their neuropsychological 
performance. No significant correlations were found between the principal measures (long-delay 
recall, C-Pittsburgh compound-B scan, left hippocampal volume, and APOEε4) and either age, 
sex, or education (P.0.1). Baseline amyloid deposition and left hippocampal volume separated 
the three diagnostic groups and correlated with the memory performance (P,0.001).
Conclusion: Cross-sectional analysis of baseline data revealed links between cognition, 
structural changes, and biomarkers. Follow-up of a larger and more representative cohort, par-
ticularly analyzing cerebrospinal fluid and brain biomarkers, will allow better characterization 
of AD in our country.
Keywords: aging, Alzheimer’s disease, amyloid imaging, biomarkers, mild cognitive 
impairment
Introduction
Rates of dementia are growing at an alarming rate globally as the world population 
ages.1 Several studies have shown that the overall prevalence of dementia varies widely 
among countries, mainly related to the influence of cultural and socioeconomic factors.2 
According to the World Health Organization, in the near future, aging of the population 
will be more pronounced in underdeveloped countries, while the People’s Republic of 
China, India and Latin America will be the areas more affected by this aging process. 
Diseases related to the aging process, such as dementia, will be more prevalent in these 
regions,3 and it is anticipated that the prevalence and incidence of Alzheimer’s disease 
(AD) will dramatically increase, especially among the group of “oldest old”.
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There is a continuum of progressive deterioration of 
cognitive abilities from normal cognition to minimal cognitive 
impairment (MCI) to dementia syndrome. Early diagnosis of 
cognitive impairment is highly recommended to help patients 
and families cope with the disease despite the current lack of 
an effective curative treatment. Worldwide, numerous new 
medications are being developed and tried in clinical trials.
Neuroimaging and chemical biomarkers performed at 
the MCI stage may allow detection of the neurodegenera-
tive process of AD at an earlier point in the spectrum.4 To 
achieve this goal, worldwide Alzheimer’s Disease Neu-
roimaging Initiative (ADNI) researchers have established 
a longitudinal multicenter study designed to develop clini-
cal, imaging, genetic, and biochemical biomarkers for the 
early detection and tracking of AD. The methodological 
organization of the Argentina-ADNI is comparable with 
other worldwide ADNI programs. Since its creation, the 
Arg-ADNI5 has developed a clinical and neuropsychologi-
cal test battery and has standardized imaging techniques 
and biomarker procedures in normal subjects, subjects 
with MCI, and subjects with mild AD. The Arg-ADNI was 
designed to establish the first worldwide ADNI center in 
Latin America and to examine: 1) clinical, neuropsycho-
logical, and behavioral characteristics; 2) role of risk and 
protective factors; 3) conversion rates from MCI to dementia 
or normal cognition; and 4) biomarker data on patients 
with AD, MCI, and elderly controls. Our objective was to 
describe the baseline characteristics and to examine whether 
biomarkers related to AD physiopathology were associated 
with worse memory performance.
Patients and methods
structure and design of the study
The methodological organization of the Arg-ADNI is similar 
to other worldwide ADNI programs. The methods of Arg-
ADNI data collection and study design have been described 
in detail elsewhere.5 The Arg-ADNI team has been enroll-
ing subjects for this study since January 2012. This study 
was approved by the Medical Ethics Committee of FLENI, 
Buenos Aires, Argentina. Written informed consent was 
obtained from all participants and/or their legally acceptable 
representative.
subject recruitment and selection of 
patients
Enrolled subjects were between 55 and 90 years of 
age (inclusive), and we admitted subjects with normal 
cognition (controls), MCI, and AD. We required patients 
to have a study partner (such as a family member or close 
friend) to provide an independent evaluation of daily 
functioning.
Participants underwent a “screening” visit, during which 
they completed the Mini-Mental State Examination (MMSE), 
Wechsler’s Logical Memory Scale – Revised (LM; Immedi-
ate and Delayed Recall), Clinical Dementia Rating (CDR; 
Global and Sum of Boxes), and Geriatric Depression Scale 
(GDS). They then underwent a “baseline” visit, at which 
point they completed the neuropsychological battery, and 
underwent all test procedures, including neuroimaging and 
APOE genotyping. According to the ADNI-2 procedure 
manual, the window from “screening” to “baseline” was 
28 days. Participants were then followed longitudinally 
(6–12 month follow-up visits).
Neuropsychological battery
At baseline and 1-year follow-up, subjects were evaluated 
using the Alzheimer’s Disease Assessment Scale, Montreal 
Cognitive Assessment, Clock Drawing Test, Auditory 
Verbal Learning Test (RAVLT; Total, delayed recall, 
recognition score), Boston Naming Test, Animal Fluency, 
Letter Fluency, Trail Making Tests A and B, Neuropsy-
chiatric Inventory Q, GDS, and Functional Assessment 
Questionnaire (FAQ).
structural magnetic resonance imaging 
scans
All subjects underwent a 3-Tesla magnetic resonance 
imaging (MRI) scan of the brain including T1, T2, fluid-
attenuated inversion recovery, and gradient-recalled echo, 
and diffusion-weighted imaging sequences, and images 
were then saved in Kodak Carestream System from FLENI 
for clinical reviewing.
Cortical reconstruction and volumetric segmentation 
were performed with the automated volumetric output of 
the FreeSurfer image analysis suite, which is documented 
and freely available for download online (http://surfer.nmr.
mgh.harvard.edu/). FreeSurfer analysis was completed using 
Version 4.3. The volumetric and cortical thickness measures 
were corrected for the total intracranial volume. The techni-
cal details of these procedures have been described in prior 
publications.6,7
We determined three regions of interest to be measured: 
the amygdala, hippocampus, and parahippocampal gyrus. 
The rationale for regions of interest selection was based on 
which regions have been previously reported as selectively 
affected by AD in the most of published studies.





amyloid positron emission tomography 
scans (11c-Pittsburgh compound B)
Positron emission tomography (PET) with fluorodeoxyglu-
cose (FDG) and 11C-Pittsburgh compound-B (PIB-PET) was 
performed in every subject. The synthesis of 11C-PIB was 
performed in the Tracer LAB FXCPRO (General Electric RIS 
[Radiology Information System] Carestream). After 50 minutes 
of the endovenous infusion of 10 mCi of 11C-PIB, volumetric 
multislice computerized tomography (CT) brain images were 
obtained using PET/CT Discovery 690 GE equipment (General 
Electric RIS – Radiology Information System – Carestream). 
Images were obtained using a nonuniform attenuation correc-
tion with CT. Images were viewed and analyzed by a nuclear 
medicine physician blinded to the clinical diagnosis. Based on 
the concentration of activity of 11C-PIB, the degree of corti-
cal retention was classified as positive (β+) or negative (β−) 
using visual color linear scales. No other semiquantitative or 
quantitative assay was performed from the PET images. We 
also recorded cerebral metabolism using FDG-PET scans. 
However, results were not considered in this analysis.
aPOe genotyping
In line with other ADNI studies, APOE genotyping for all 
participants was performed as previously described.5 The 
presence of at least one ε4 allele was considered as being 
APOE-ε4 positive (ε4+).
Cerebrospinal fluid biomarkers
At least 80% of the participants donated a sample of cerebro-
spinal fluid (CSF) via a lumbar puncture. FLENI scientists 
then run CSF biomarkers using enzyme-linked immuno-
sorbent assay kits (Innogenetics; Ghent, Belgium) and our 
laboratory participates in the ADNI Quality Control Program. 
CSF markers included the determination of amyloid β1–42, 
total tau protein (t-tau), and tau phosphorylated at position 
threonine 181 (p-tau181).
consensus diagnoses
After each clinical assessment, study neurologists (RFA, 
MJR, and PC) and neuropsychologists (MEM, MFC, PH, and 
FT) reviewed the functional, neurologic, and neuropsycho-
logical data and reached a consensus regarding the presence 
or absence of dementia based on the National Institute of 
Neurological and Communicative Disorders and Stroke–
Alzheimer’s Disease and Related Disorders Association 
criteria for probable AD.8 Only those who were not diagnosed 
with dementia were considered for a diagnosis of MCI, which 
was defined according to Petersen’s criteria.9
Data analysis
Statistical analyses were performed with the Statistical 
Package for the Social Sciences, v19.0 (SPSS Inc., Chicago, 
IL, USA). Continuous variables were expressed as mean 
(standard deviation [SD]), and categorical variables were 
expressed as frequencies (%). The χ2 test was used for com-
parison of categorical variables. The proportion of subjects 
“who converted” to dementia was determined (conversion 
rate % = total conversions/total MCI subjects ×100). 
Normality was tested using the Shapiro–Wilk test. Assump-
tion of variance homogeneity was assessed using Levene’s 
test. Analysis of variance (ANOVA) or one-way ANOVA 
was used for comparisons of continuous variables if the 
samples were distributed normally. If samples were not 
distributed normally, Kruskal–Wallis one-way ANOVA was 
used. For multiple comparisons, Bonferroni’s post hoc tests 
were applied. Conversion proportion was estimated. Differ-
ences between the mean values were considered statistically 
significant at P,0.05.
The relationship between memory performance measured 
by long-delay recall on RAVLT and several factors related 
to AD physiopathology was examined by logistic regres-
sion analyses. The full data set was split into two groups 
to determine which variables were consistent predictors of 
poor memory performance. Due to skewed distributions of 
the long-delay recall on the RAVLT, we split the variable 
at its median to create a dichotomous variable (#3 poor 
performance or .3 good performance). The potential pre-
dictors for memory performance were chosen based on the 
known pathologies and biomarkers of AD and constituted 
the main analysis. The independent variables of interest 
were the result of PIB-PET scan, APOEε4 carrier, and left 
hippocampal volume. The primary dependent variable was 
long-delay free recall on the RAVLT. PIB-PET scan and 
APOEε4 status were entered into the model as dichotomous 
variables (ie, positive or negative PIB-PET and presence or 
absence of at least one ε4 allele). The models were estimated 
using the stepwise forward likelihood ratio method.
Results
Baseline characteristics of study subjects
Information related to the demographic characteristics of 
the participant groups are summarized in Table 1. A total 
of 56 participants were included and underwent baseline 
evaluation. There were 15 normal controls, 28 subjects with 
MCI, and 13 with mild AD dementia enrolled in this study. 
The three groups were similar with respect to years of 
education and sex, and they differed in age (AD patients 





were older than the rest). All subjects were white and Spanish 
speaking. For the AD and MCI groups, the mean time from 
symptom onset to enrollment in Arg-ADNI was ~3 years. 
The mean number of total medications per participant in 
the Arg-ADNI cohort was 3.5 (SD: 1.85). At baseline, 46% 
(n=12) of MCI participants and 80% (n=10) of AD subjects 
received treatment with a cholinesterase inhibitor. One 
patient in the MCI group and two AD patients were treated 
also with memantine.
Table 2 shows the mean scores for the screening mea-
sures (MMSE, Paragraph Recall, CDR, GDS, and Modified 
Hachinski Scale). As expected, there was a statistically sig-
nificant difference in the baseline screening test results in the 
three groups (P,0.001) for the MMSE, Paragraph Recall, 
and CDR, with the exception of the GDS and Modified 
Hachinski Scale scores, in which the difference in all three 
groups did not reach significance (P=0.27 and 0.69).
As shown in Table 3, the mean scores for the baseline 
measurements of the neuropsychological evaluation differed 
significantly among the three groups at P,0.001, showing a 
continuum in their neuropsychological performance. Overall, 
subjects with mild AD had a mean total Montreal Cognitive 
Assessment score of 16.5, whereas the MCI subjects had a 
score of 22.9 and the control subjects had a score of 26.6. 
The subjects with AD performed worse than control and 
MCI subjects on Clock Drawing Test (P,0.001) and Clock 
Copying Test (P=0.01), although no differences between the 
MCI and control groups were observed. The three groups dif-
fered significantly in the total number of recalled words, as 
well as in short-delay (Trial 6) and long-delay (Trial 7) recall 
from RAVLT, and there was no statistical significance in the 
number of intrusions in the delayed recall, recognition score, 
and the number of false alarms. The AD subjects were also 
impaired in all nonmemory areas tested, including language 
and executive functions. MCI subjects performed worst 
compared to control in executive functions domain (Letter 
Fluency and Trail Making Test). There was no statistical 
significant difference in behavioral symptoms using the NPI 
Table 1 Demographic characteristics of the participant groups







age, mean ± sD, years 64.9 8.1 70.1 6.8 73.1 5.5 5.10 0.01 a
sex (male/female) 5/10 13/15 6/7 0.76 0.68
education, mean ± sD, years 14.5 3.4 13.1 4.4 12.2 3.9 1.26 0.29
symptom onset, mean ± sD, years Na 2.9 2.7 3.2 3.7 0.08 0.78
Baseline medication
Total number of medications, mean ± sD 2.3 2.0 4.0 1.6 4.1 1.6 5.85 0.01 a, c
cholinesterase inhibitors, n 0 13 10 17.69 ,0.001 a, c
Memantine, n 0 1 2 3.60 0.17
antidepressants, n 1 10 4 3.60 0.17
antipsychotics, n 0 2 5 2.98 0.23
carriers aPOeε4, % 38.5 36.8 44.4 0.15 0.93
Notes: *Multiple comparisons abbreviated as a: controls differ from subjects with aD, b: subjects with Mci differ from subjects with aD, c: controls differ from subjects with 
Mci. The χ2 test was used for comparison of categorical variables. One-way aNOVa was used for comparisons of continuous variables.
Abbreviations: aD, alzheimer’s disease; Mci, mild cognitive impairment; sD, standard deviation.
Table 2 screening assessments
Variables Controls (n=15) MCI (n=28) AD (n=13) ANOVA
M SD M SD M SD F P-value P,0.05*
MMse13 29.2 1.5 28.6 1.3 22.0 3.2 60.16 ,0.001 a, b
lM immediate recall14 10.2 2.6 6.3 3.3 2.3 1.8 27.42 ,0.001 a, b, c
lM delayed recall14 7.9 2.2 3.8 3.5 0.5 1.1 25.68 ,0.001 a, b, c
gDs-1515 1.7 1.5 2.4 2.3 1.5 1.1 1.35 0.27
cDr – screening16 0.0 0.1 0.5 0.0 0.7 0.3 89.72 ,0.001 a, b, c
cDr-sOB – screening16 0.0 0.1 1.0 0.8 3.7 1.6 55.62 ,0.001 a, b, c
Modified Hachinski17 0.3 0.8 0.2 0.5 0.3 0.5 0.37 0.69
Notes: *Multiple comparisons abbreviated as a: controls differ from subjects with aD, b: subjects with Mci differ from subjects with aD, c: controls differ from subjects 
with Mci. © 2012 Used with the permission of the alzheimer’s Disease Neuroimaging initiative.13–17
Abbreviations: aD, alzheimer’s disease; Mci, mild cognitive impairment; MMse, Mini–Mental state examination; lM, logical memory; gDs, geriatric Depression scale; 
cDr, clinical Dementia rating; cDr-sOB, clinical Dementia rating-sum of Boxes; aNOVa, analysis of variance; sD, standard deviation.





reported by family members in the three groups, although 
we saw a trend toward more behavioral symptoms in the 
AD group compared to the rest. As expected, we observed 
a significant difference in the daily functions using FAQ 
with more impairment in the AD group compared to the 
other groups and no significant difference in performance 
of activities between the control and MCI patients. Inter-
estingly, for the MCI group, we found mild compromise 
in activities of daily living, mainly in sophisticated instru-
mental activities using the FAQ (writing checks, paying 
bills, keeping financial records; assembling tax or business 
records; and remembering appointments, family occasions, 
and medications). These data are not shown.
Biomarkers results of study subjects
Table 4 shows the results of MRI and CSF biomarkers. 
Regarding volumetric MRI measurements, all regions of 
interest measured (amygdala, hippocampus, and parahip-
pocampal gyrus) were significantly different (P,0.05) in 
control subjects compared to MCI and AD subjects, but 
interestingly, there were no differences between the MCI 
and AD groups. As outlined in the ADNI protocol, we then 
Table 4 Biomarkers results
Variables Controls MCI AD χ² P-value P,0.05*
Volumetric Mri measurements (mm³), mean ± sD (n=15) (n=28) (n=13)
left hippocampus 4,127.7 727.2 3,300.6 730.6 2,867.5 696.6 16.12 ,0.001 a, c
left amygdala 1,440.4 324.2 1,176.5 297.0 989.8 251.9 12.78 ,0.001 a, c
left parahippocampal gyrus 3,806.6 639.1 3,290.9 842.0 2,714.0 645.8 11.45 ,0.001 b
right hippocampus 4,161.0 743.4 3,235.7 627.0 2,782.0 618.3 18.61 ,0.001 a, c
right amygdala 1,605.6 339.8 1,243.5 259.7 1,176.9 252.4 12.94 ,0.001 a, c
right parahippocampal gyrus 4,161.8 813.7 3,498.6 676.3 2,945.6 774.5 15.02 ,0.001 a, c
csF biomarkers (pg/ml), mean ± sD (n=10) (n=21) (n=8)
abeta 824.2 256.5 678.8 353.3 423.8 269.3 8.24 0.02 a, b
Tau total 207.4 76.3 379.9 264.1 596.4 261.2 8.67 0.01 a, b
p-Tau 37.5 12.5 61.9 42.7 78.5 27.1 5.79 0.06
Positive amyloid PeT, % 14.2 50.0 83.3 12.41 ,0.001 a, b, c
Notes: *Multiple comparisons abbreviated as a: controls differ from subjects with aD, b: subjects with Mci differ from subjects with aD, c: controls differ from subjects 
with Mci.
Abbreviations: AD, Alzheimer’s disease; MCI, mild cognitive impairment; MRI, magnetic resonance imaging; CSF, cerebral spinal fluid; PET, positron emission tomo­
graphy.
Table 3 Baseline assessments
Variables Controls (n=15) MCI (n=28) AD (n=13) ANOVA
M SD M SD M SD F P-value P,0.05*
Moca18 26.6 4.0 22.9 3.5 16.5 3.9 24.22 ,0.001 a, b, c
clock Drawing19 5.0 0.0 4.4 1.0 2.77 1.6 16.31 ,0.001 a, b
clock copying19 5.0 0.0 5.0 0.2 4.4 1.2 4.76 0.01 a, b
raVlT Total20 42.9 8.3 30.4 8.6 20.2 6.8 26.20 ,0.001 a, b, c
raVlT immediate recall20 9.3 3.7 4.40 2.3 2.0 1.8 25.14 ,0.001 a, b, c
raVlT delayed recall20 8.2 2.4 3.3 2.5 0.4 0.8 47.51 ,0.001 a, b, c
intrusions Delayed20 0.5 0.6 0.9 1.6 0.1 0.3 2.05 0.14
raVlT recognition score20 8.5 6.3 5.4 5.3 4.7 4.2 2.11 0.13
False alarms20 0.1 0.3 1.1 2.1 1.5 1.9 2.75 0.07
Boston Naming Test21 26.0 7.6 25.5 5.8 20.0 5.5 4.12 0.02 a, b
category Fluency (animals)22 21.5 3.4 17.6 3.2 12.1 4.0 26.21 ,0.001 a, b, c
letter Fluency (“p”)22 19.5 4.3 15.6 5.3 13.5 5.0 5.29 0.01 a
Trail Making a (seconds)23 33.8 8.7 51.1 21.4 125.5 121.4 9.22 ,0.001 a, b
Trail Making B (seconds)23 75.8 29.1 143.4 86.7 288.9 97.0 26.77 ,0.001 a, b, c
NPi24 0.4 0.7 4.1 5.5 9.5 15.6 2.77 0.08
FaQ25 0.0 0.0 3.2 0.4 12.8 9.8 15.05 ,0.001 a, b
Notes: *Multiple comparisons abbreviated as a: controls differ from subjects with aD, b: subjects with Mci differ from subjects with aD, c: controls differ from subjects 
with Mci. © 2012 Used with the permission of the alzheimer’s Disease Neuroimaging initiative.18–25
Abbreviations: aD, alzheimer’s disease; Mci, mild cognitive impairment; Moca, Montreal cognitive assessment; raVlT, auditory Verbal learning Test (Total, delayed 
recall, recognition score); NPi, Neuropsychiatric inventory; FaQ, Functional assessment Questionnaire; aNOVa, analysis of variance; sD, standard deviation.





considered the MCI group and split it into early versus 
late MCI, and we found a significantly lower hippocampal 
volume in subjects with late MCI compared to controls, and 
no statistical difference between controls and those with early 
MCI (Figure 1).
CSF results were available from ten control subjects, 
21 patients with MCI, and eight patients with mild AD. 
Baseline CSF Aβ-42 levels decreased significantly across the 
groups (P,0.05) with a slope of values from the control sub-
jects to MCI and AD patients. Baseline t-tau levels increased 
significantly (P,0.05) and p-tau levels increased margin-
ally (P=0.06) across the groups. There were no differences 
between the controls and MCI groups in CSF biomarkers. 
All subjects underwent an amyloid PET scan. The following 
percentages of subjects had an amyloid positive (Aβ+) PET 
scans at baseline: normal controls: 14.2%, subjects with MCI: 
50%, and subjects with mild AD: 83.3%, with a significant 
difference in percentage distribution across diagnostic groups 
(P=0.002; Figure 2).
Prediction of memory performance main 
analyses
A logistic regression analysis was conducted for successfully 
predicting the memory performance of the patient population 
using PIB-PET scan, left hippocampal volume, and APOEε4 
status as predictors. No significant correlations were found 
between the principal measures (long-delay recall, PIB-PET 
scan, left hippocampal volume, and APOEε4) and either 
age, sex, or education (P.0.1). Consequently, these mea-
sures were not considered for further analysis. A test of the 
full model against a constant-only model was statistically 
significant, indicating that the predictors as a set reliably dis-
tinguished between individuals having a long-delay recall on 
RAVLT of ,3 with those having a higher score (χ2=14.802, 
P,0.001 with df=1).
Nagelkerke’s R2 of 0.711 indicated a moderately strong 
relationship between prediction and grouping (Table 5). 
Prediction success overall was 87.5% (85% for good 
performance and 90% for poor performance). The Wald 
criterion demonstrated that only PIB-PET scan and left 
hippocampal volume made a significant contribution to 
prediction (P=0.01). APOEε4 status was not a significant 
predictor (Figure 3).
Discussion
This report presents the clinical and biomarkers profile of the 
baseline evaluation of Arg-ADNI. Our study is a longitudinal 
prospective cohort study of 56 subjects, aged 55–90 years 
recruited at a single study site in Argentina. Our institution is 
the only medical center in the region with the infrastructure 
to perform the biomarkers and PET study with Pittsburg 
compound. All the procedures and follow-up were performed 
at our center with highly standardized protocols and strictly 
adhered to worldwide study sites. By following the ADNI-II 
Figure 1 Mri volumetry of left hippocampus in argentina-aDNi subjects.
Abbreviations: aD, alzheimer’s disease; eMci, early mild cognitive impairment; 
LMCI, late mild cognitive impairment; ns, nonsignificant; MRI, magnetic resonance 
imaging; aDNi, alzheimer’s Disease Neuroimaging initiative.
Figure 2 Percentage of amyloid positive (aβ+) and negative (aβ−) PeT scans at 
baseline in arg-aDNi.
Abbreviations: aD, alzheimer’s disease; Mci, mild cognitive impairment; PeT, positron 
emission tomography; arg-aDNi, argentina-alzheimer’s Disease Neuroimaging 
initiative; 11c PiB-PeT, 11c-Pittsburgh compound-B.





recruitment protocol, Arg-ADNI represents a similar cohort 
to other clinical studies.4
The summary of the baseline characteristics of the 
Arg-ADNI subjects showed that the three groups were 
comparable to subjects recruited at other worldwide ADNI 
sites.4 Neuropsychology, structural, and molecular measures 
showed a continuum between the three groups, with AD 
being the worst group, controls better, and MCI subjects 
showing an intermediate status (especially, long-delay recall, 
hippocampal volume, amyloid deposition measured by PIB-
PET and CSF). Furthermore, the amyloid deposition and 
hippocampal atrophy data highly correlated with the memory 
performance. Similar findings have arisen in related studies 
supporting the use of hippocampal volume and amyloid 
deposition as reliable and valid surrogate measures in AD 
clinical drug trials.10,11
We observed that almost half the patients in the MCI 
group received medication with cholinesterase inhibitor. 
Treatment with this group of medications for MCI is cur-
rently out off label for this diagnosis, and it is interesting to 
observe that the clinical practice of neurologists in our center 
that did not differ from that reported in other ADNI sites.4,12 
Very few patients in this group of patients with only mild 
AD were treated with memantine, which is consistent with 
the current indication of this drug restricted to moderate-to-
severe AD.
Conclusion
Limitations of our study are, in the first place, the relatively 
small cohort of subjects included in this first pilot study. This 
is in part due to funding constraints for research in developing 
countries. Another limitation is that our study was performed 
in a unique, single-specialized medical center, and thus could 
be less representative of the real population of patients of our 
region. All investigators from this pilot team hope to develop 
a new pathway to create a multisite ADNI in Argentina, with 
the intention of using these preliminary results obtained to 
seek continued funding from local and international agen-
cies. Follow-up of a larger and more representative cohort, 
particularly related to CSF and brain biomarkers, will allow 
for better characterization of AD in our country, and perhaps 
point to unique environmental factors influencing brain health 
in South America.5
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Figure 3 logistic regression results.
Notes: The plot of logistic regression Model displays the probability of the 
outcome (memory performance) versus significant predictor variables (PIB­PET 
scans and left hippocampal volume), with the other variables held constant.
Abbreviation: 11c PiB-PeT, 11c-Pittsburgh compound-B.
Table 5 summary of logistic regression analysis predicting memory performance
Model terms B SE Wald P-value −2LL Nagelkerke’s R2 Percentage 
correct
intercept 0.0 0.3 0.00 1.00 55.452 50.0
step 1: PiB-PeT positive −2.833 0.812 12.184 ,0.001 39.802 0.432 80.0
step 2: PiB-PeT positive −2.659 1.038 6.567 0.01 25.000 0.711 87.5
left hippocampal volume −0.003 0.001 6.747 0.01
Notes: The dependent variable in this analysis was memory performance measured by long-delay recall on raVlT coded so that 0= .3 (good performance) and 1= #3 
(poor performance). The independent variables of interest were the result of PiB-PeT scan, aPOe ε4 carrier, and left hippocampal volume. The models were estimated using 
the stepwise forward lr method.
Abbreviations: PiB-PeT, 11c-Pittsburgh compound-B; raVlT, auditory Verbal learning Test (Total, delayed recall, recognition score); lr, likelihood ratio.
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